Roche: FDA approves Gavreto
(CercleFinance.com) - Roche has announced that the FDA has approved Gavreto (pralesetinib) for the treatment of adult patients with metastatic RET-fusion positive non-small cell lung cancer.
This treatment has been approved under the FDA's accelerated approval programme, based on data from the ARROW Phase I/II trial.
Gavreto is a once-daily oral treatment that selectively inhibits cancers altered by RET. Genentech and Blueprint Medicines will jointly market Gavreto in the United States.
The FDA has also granted priority review to Gavreto for the treatment of patients with advanced or metastatic RET-mutated spinal cord cancer and RET-positive thyroid cancer.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
This treatment has been approved under the FDA's accelerated approval programme, based on data from the ARROW Phase I/II trial.
Gavreto is a once-daily oral treatment that selectively inhibits cancers altered by RET. Genentech and Blueprint Medicines will jointly market Gavreto in the United States.
The FDA has also granted priority review to Gavreto for the treatment of patients with advanced or metastatic RET-mutated spinal cord cancer and RET-positive thyroid cancer.
Copyright (c) 2020 CercleFinance.com. All rights reserved.